Cancer Harboring BRAF Alterations

1

Review clinical trials related to Cancer Harboring BRAF Alterations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

Participants needed: 254
Trial details
Phase: Phase 2Age: 10+Biological sex: AllType: InterventionalSponsor: Fore BiotherapeuticsUpdated: Jun 5, 2026Locations: 70
Eligibility criteria

Male and female, ≥10 years of age, and weighing ≥30 kg. [+30]

Prior treatment with RAF/BRAF inhibitors active for Class 2 BRAF alterations for... [+30]